Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry. In today’s Pharmaceutical Executive Daily, we cover the impact of Novo Nordisk layoffs on its hometown in Denmark, GSK’s appointment of Luke Miels as its next CEO, and the FDA’s approval of Regeneron’s Evkeeza for children with homozygous familial hypercholesterolemia. In Denmark, the town surrounding Novo Nordisk’s headquarters is bracing for the impact of significant layoffs as part of the company’s global restructuring. In leadership news, GSK has named Luke Miels as its next chief executive officer. Thanks for listening to Pharmaceutical Executive Daily.